A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

ישראלמגייס משתתפיםPHASE1, PHASE2

מצבים רפואיים

Small Cell Lung Cancer

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • University of Colorado Anschutz Medical Campus ( Site 1110), Aurora, Colorado, United States

    Study coordinator · 303-724-6268
  • University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1111), Miami, Florida, United States

    Study coordinator · 305-243-1754
  • University of Chicago ( Site 1108), Chicago, Illinois, United States

    Study coordinator · 773-702-6149
  • Dana Farber Cancer Institute ( Site 1105), Boston, Massachusetts, United States

    Study coordinator · 617-632-6049
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103), Hackensack, New Jersey, United States

    Study coordinator · 551-996-5863
  • Roswell Park Cancer Institute ( Site 1107), Buffalo, New York, United States

    Study coordinator · 716-845-3167
  • Providence Portland Medical Center ( Site 1101), Portland, Oregon, United States

    Study coordinator · 503-215-5696
  • Sarah Cannon Research Institute ( Site 7001), Nashville, Tennessee, United States

    Study coordinator · 844-482-4812
  • Medical College of Wisconsin ( Site 1112), Milwaukee, Wisconsin, United States

    Study coordinator · 414-805-8900
  • Hospital Universitario Austral ( Site 2204), Pilar, Buenos Aires, Argentina

    Study coordinator · 02304482000
  • Sanatorio Parque ( Site 2203), Rosario, Santa Fe Province, Argentina

    Study coordinator · +5493416955611
  • Princess Alexandra Hospital ( Site 5300), Woolloongabba, Queensland, Australia

    Study coordinator · +61731766577
  • Monash Health ( Site 5301), Clayton, Victoria, Australia

    Study coordinator · +61417607416
  • FALP ( Site 2100), Santiago, Region M. de Santiago, Chile

    Study coordinator · +56224205098
  • Pontificia Universidad Catolica de Chile ( Site 2102), Santiago, Region M. de Santiago, Chile

    Study coordinator · +5690233407
  • Bradfordhill ( Site 2101), Santiago, Region M. de Santiago, Chile

    Study coordinator · +56229490970
  • Beijing Cancer Hospital ( Site 5401), Beijing, Beijing Municipality, China

    Study coordinator · (010) 88121122
  • Fujian Cancer Hospital ( Site 5413), Fuzhou, Fujian, China

    Study coordinator · 0591-62002053
  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology ( Site 5403), Nanjing, Jiangsu, China

    Study coordinator · 025-83106666
  • Shanghai Chest Hospital ( Site 5400), Shanghai, Shanghai Municipality, China

    Study coordinator · 021-22200000
  • Shanghai Pulmonary Hospital ( Site 5405), Shanghai, Shanghai Municipality, China

    Study coordinator · 15801709047
  • West China Hospital of Sichuan University ( Site 5416), Chengdu, Sichuan, China

    Study coordinator · 02885423237
  • The First Affiliated Hospital, Zhejiang University ( Site 5404), Hangzhou, Zhejiang, China

    Study coordinator · 13675843246
  • Rambam Health Care Campus ( Site 3202), Haifa, Israel

  • Shaare Zedek Medical Center ( Site 3200), Jerusalem, Israel

    Study coordinator · 026555768
  • Rabin Medical Center ( Site 3203), Petah Tikva, Israel

    Study coordinator · +97239378101
  • Sheba Medical Center ( Site 3201), Ramat Gan, Israel

    Study coordinator · 97235304498
  • Aichi Cancer Center ( Site 5000), Nagoya, Aichi-ken, Japan

    Study coordinator · +81-52-762-6111
  • National Cancer Center Hospital East ( Site 5001), Kashiwa, Chiba, Japan

    Study coordinator · +81-4-7133-1111
  • Kansai Medical University Hospital ( Site 5004), Hirakata, Osaka, Japan

    Study coordinator · +81-72-804-2808
  • Cancer Institute Hospital of JFCR ( Site 5002), Koto, Tokyo, Japan

    Study coordinator · +81-3-3520-0111
  • Seoul National University Hospital ( Site 5100), Seoul, South Korea

    Study coordinator · +82220723559
  • Severance Hospital, Yonsei University Health System ( Site 5102), Seoul, South Korea

    Study coordinator · +82215991004
  • Samsung Medical Center ( Site 5101), Seoul, South Korea

    Study coordinator · +82234101795
  • HOSPITAL CLÍNIC DE BARCELONA ( Site 3310), Eixample, Barcelona, Spain

    Study coordinator · +34932275402
  • Institut Català d'Oncologia - L'Hospitalet ( Site 3317), L'Hospitalet de Llobregat, Barcelona, Spain

    Study coordinator · +34932607744
  • Hospital Clinico San Carlos... ( Site 3316), Madrid, Madrid, Comunidad de, Spain

    Study coordinator · 34913303000x484804
  • Hospital Universitari Vall d'Hebron ( Site 3311), Barcelona, Spain

    Study coordinator · +34934894158
  • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 3315), Madrid, Spain

    Study coordinator · +34915504800ext2805
  • Hospital Universitario HM Sanchinarro ( Site 3313), Madrid, Spain

    Study coordinator · +34917567984
  • Hospital Universitario Virgen de la Victoria ( Site 3312), Málaga, Spain

    Study coordinator · +34671594566
  • National Cheng Kung University Hospital ( Site 5202), Tainan, Taiwan

    Study coordinator · +88662353535
  • Taipei Medical University Hospital ( Site 5201), Taipei, Taiwan

    Study coordinator · +886227372181
  • Hacettepe Universite Hastaneleri ( Site 3410), Ankara, Turkey (Türkiye)

    Study coordinator · +903123055000
  • Ankara Bilkent Sehir Hastanesi ( Site 3412), Ankara, Turkey (Türkiye)

    Study coordinator · +90312 552 6084
  • National Institute for Health Research UCLH Clinical Research Facility ( Site 3902), London, London, City of, United Kingdom

    Study coordinator · +442034472930
  • The Clatterbridge Cancer Centre ( Site 3903), Liverpool, United Kingdom

    Study coordinator · 00441515565000
  • The Christie NHS Foundation Trust ( Site 3901), Manchester, United Kingdom

    Study coordinator · +441614463000
מובילי המחקר
  • Medical Director

    Study Director

    Merck Sharp & Dohme LLC